Related Experiment Video
Updated: Jul 18, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
Atopic dermatitis and the atopic march
Jonathan M Spergel1, Amy S Paller
1Division of Allergy and Immunology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Insights
Atopic dermatitis (AD) affects infants and children, negatively impacting quality of life and leading to other allergic conditions like asthma. Early intervention may help slow this progression, known as the atopic march.
Area of Science:
- Pediatric Dermatology
- Allergology
- Immunology
Background:
- Atopic dermatitis (AD) is a prevalent skin disorder in infants and children, with increasing incidence globally.
- AD significantly impacts patient and family quality of life, causing sleep disturbances and financial burdens.
- The condition often initiates the 'atopic march,' a progression to other allergic diseases.
Purpose of the Study:
- To review the characteristics, impact, and progression of atopic dermatitis.
- To explore the concept of the atopic march and its underlying mechanisms.
- To discuss potential early intervention strategies for atopic dermatitis.
Main Methods:
- Review of longitudinal studies on atopic dermatitis progression.
- Analysis of epidemiological data on atopic dermatitis prevalence.
- Examination of immunological theories regarding epicutaneous sensitization and T cell migration.
Main Results:
- Approximately 50% of AD patients develop asthma, and 66% develop allergic rhinitis, especially with severe AD.
- Epicutaneous sensitization is hypothesized to drive the atopic march via T cell migration to airways.
- Preliminary studies suggest oral antihistamines may slow the atopic march.
Conclusions:
- Atopic dermatitis is a critical early manifestation of allergic disease with significant long-term implications.
- Understanding the atopic march is crucial for developing effective prevention and treatment strategies.
- Early intervention, potentially with oral antihistamines, shows promise in mitigating the progression of atopic diseases.
Abstract:
Atopic dermatitis (AD), one of the most common skin disorders seen in infants and children, usually has its onset during the first 6 months of life. The prevalence of AD is similar in the United States, Europe, and Japan and is increasing, similar to that of other atopic disorders, particularly asthma. AD has been classified into 3 sequential phases: infantile, childhood, and adult, each with characteristic physical findings. AD has a tremendously negative effect on the quality of life of patients as well as family, most commonly disturbing sleep. The condition also creates a great financial burden for both the family and society. The cutaneous manifestations of atopy often represent the beginning of the atopic march. On the basis of several longitudinal studies, approximately half of AD patients will develop asthma, particularly with severe AD, and two thirds will develop allergic rhinitis. Epicutaneous sensitization has been thought to be responsible, with subsequent migration of sensitized T cells into the nose and airways, causing upper and lower airway disease. Animal models and human observation concur with this theory. Preliminary prevention studies with oral antihistamines provide evidence that early intervention might slow the atopic march.
Related Concept Videos
Allergic Reactions
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-I: Introduction
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma I: Introduction
Asthma III: Clinical Manifestations

